Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 2, 2006, Pages 580-586

  Miyazaki, Taiga ^a,c   Miyazaki, Yoshitsugu ^a   Izumikawa, Koichi ^a   Kakeya, Hiroshi ^a   Miyakoshi, Shunichi ^b   Bennett, John E ^c   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIHYDROERGOSTEROL; C 5,6 STEROL DESATURASE; EPISTEROL; ERGOSTEROL; FECOSTEROL; FLUCONAZOLE; ITRACONAZOLE; LANOSTEROL; MICONAZOLE; STEROL; UNCLASSIFIED DRUG; VORICONAZOLE;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG EFFICACY; ERG3 GENE; FATTY ACID DESATURATION; FEMALE; FUNGAL VIRULENCE; FUNGICIDE RESISTANCE; GENE; GENE LOCUS; GENE MUTATION; HOMOZYGOTE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; URA BLASTER METHOD; WILD TYPE;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTATION; OXIDOREDUCTASES; STEROLS; VIRULENCE;

EID: 31944440019     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.580-586.2006     Document Type: Article

References (41)

1. Anderson, J. B. 2005. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 3:547-556.
2. Aoyama, Y., Y. Yoshida, and R. Sato. 1984. Yeast cytochrorae P-450 catalyzing lanosterol 14 alpha-demethylation. II. Lanosterol metabolism by purified P-450(14)DM and by intact microsomes. J. Biol. Chem. 259:1661-1666.
3. Brand, A., D. M. MacCallum, A. J. Brown, N. A. Gow, and F. C. Odds. 2004. Ectopic expression of URA3 can influence the virulence phenotypes and proteome of Candida albicans but can be overcome by targeted reintegration of URA3 at the RPS10 locus. Eukaryot. Cell 3:900-909.
4. 5'6-desaturase attenuates virulence in Candida albicans. Antimicrob. Agents Chemother. 49:3646-3651.
5. Cheng, S., M. H. Nguyen, Z. Zhang, H. Jia, M. Handneld, and C. J. Clancy. 2003. Evaluation of the roles of four Candida albicans genes in virulence by using gene disruption strains that express URA3 from the native locus. Infect. Immun. 71:6101-6103.
6. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission of Life Sciences, National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
7. Ernst, J. F. 2000. Transcription factors in Candida albicans - environmental control of morphogenesis. Microbiology 146(Part 8):1763-1774.
8. Fonzi, W. A., and M. Y. Irwin. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.
9. Geber, A., C. A. Hitchcock, J. E. Swartz, F. S. Pullen, K. E. Marsden, K. J. Kwon-Chung, and J. E. Bennett. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39:2708-2717.
10. Gillum, A. M., E. Y. Tsay, and D. R. Kirsch. 1984. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol. Gen. Genet. 198:179-182.
11. Hemmi, K., C. Julmanop, D. Hirata, E. Tsuchiya, J. Y. Takemoto, and T. Miyakawa. 1995. The physiological roles of membrane ergosterol as revealed by the phenotypes of syr1/erg3 null mutant of Saccharomyces cerevisiae. Biosci. Biotechnol. Biochem. 59:482-486.
12. Henry, K. W., J. T. Nickels, and T. D. Edlind. 2000. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 44:2693-2700.
13. Hitchcock, C. A., K. Dickinson, S. B. Brown, E. G. Evans, and D. J. Adams. 1989. Purification and properties of cytochrome P-450-dependent 14 alphasterol demethylase from Candida albicans. Biochem. J. 263:573-579.
14. Johnson, E. M., D. W. Warnock, J. Luker, S. R. Porter, and C. Scully. 1995. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J. Antimicrob. Chemother. 35:103-114.
15. Kakeya, H., Y. Miyazaki, H. Miyazaki, K, Nyswaner, B. Grimberg, and J. E. Bennett. 2000. Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob. Agents Chemother. 44:2985-2990.
16. Kelly, R., S. M. Miller, M. B. Kurtz, and D. R. Kirsch. 1987. Directed mutagenesis in Candida albicans: one-step gene disruption to isolate ura3 mutants. Mol. Cell. Biol. 7:199-208.
17. Kelly, S. L., D. C. Lamb, A. J. Corran, B. C. Baldwin, and D. E. Kelly. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol. Biochem. Biophys. Res. Commun. 207:910-915.
18. Kelly, S. L., D. C. Lamb, D. E. Kelly, N. J. Manning, J. Loeffler, H. Hebart, U. Schumacher, and H. Einsele. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett. 400:80-82.
19. Lay, J., L. K. Henry, J. Clifford, Y. Koltin, C. E. Bulawa, and J. M. Becker. 1998. Altered expression of selectable marker URA3 in gene-disrupted Candida albicans strains complicates interpretation of virulence studies. Infect. Immun. 66:5301-5306.
20. Limjindaporn, T., R. A. Khalaf, and W. A. Fonzi. 2003. Nitrogen metabolism and virulence of Candida albicans require the GATA-type transcriptional activator encoded by GAT1. Mol. Microbiol. 50:993-1004.
21. Liu, H., J. Kohler, and G. R. Fink. 1994. Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog. Science 266:1723-1726.
22. MacCallum, D. M., and F. C. Odds. 2005. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 48:151-161.
23. Marr, K. A., T. R. Rustad, J. H. Rex, and T. C. White. 1999. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob. Agents Chemother. 43:1383-1386.
24. Miyazaki, Y., A. Geber, H. Miyazaki, D. Falconer, T. Parkinson, C. Hitchcock, B. Grimberg, K. Nyswaner, and J. E. Bennett. 1999. Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene 236:43-51.
25. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
26. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole-and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
27. Perea, S., J. L. Lopez-Ribot, W. R. Kirkpatrick, R. K. McAtee, R. A. Santillan, M. Martinez, D. Calabrese, D. Sanglard, and T. F. Patterson. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2676-2684.
28. Pierson, C. A., J. Eckstein, R. Barbuch, and M. Bard. 2004. Ergosterol gene expression in wild-type and ergosterol-deficient mutants of Candida albicans. Med. Mycol. 42:385-389.
29. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
30. Sambrook, J., and W. Russell (ed.). 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
31. Sanglard, D. 2002. Resistance of human fungal pathogens to antifungal drugs. Curr. Opin. Microbiol. 5:379-385.
32. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143(Part 2):405-416.
33. Sanglard, D., F. Ischer, T. Parkinson, D. Falconer, and J. Bille. 2003. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob. Agents Chemother. 47:2404-2412.
34. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
35. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
36. Staab, J. F., and P. Sundstrom. 2003. URA3 as a selectable marker for disruption and virulence assessment of Candida albicans genes. Trends Microbiol. 11:69-73.
37. Vanden Bossche, H., P. Marichal, J. Gorrens, D. Bellens, H. Moereels, and P. A. Janssen. 1990. Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals. Biochem. Soc. Trans. 18:56-59.
38. Vanden Bossche, H., P. Marichal, and F. C. Odds. 1994. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 2:393-400.
39. Varma, A., J. C. Edman, and K. J. Kwon-Chung. 1992. Molecular and genetic analysis of URA5 transformants of Cryptococcus neoformans. Infect. Immun. 60:1101-1108.
40. Vuffray, A., C. Durussel, P. Boerlin, F. Boerlin-Petzold, J. Bille, M. P. Glauser, and J. P. Chave. 1994. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 8:708-709.
41. White, T. C., S. Holleman, F. Dy, L. F. Mirels, and D. A. Stevens. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 46:1704-1713.